Advanced Biologic Technology and Global Drug Delivery Trends Presented at CPhI/ICSE China by Catalent Experts
Somerset, NJ, June 22, 2012 – Kent M. Payne, Ph.D., Vice President and General Manager, Catalent Biologics, and Lucy Sha, Strategic Marketing Director, Catalent Development and Clinical Services will be presenting on advanced biologic technology and global drug delivery trends at CPhI/ICSE China, being held in Shanghai, China on June 26-28, 2012.
Dr. Payne will discuss the results of a comparison performed between Catalent's proprietary GPEx® technology and traditional cell line engineering technology. No significant difference was observed for the easy-to-express antibody between the two approaches, however, for the other three problem molecules, GPEx® technology equivalent cell lines outperformed in both protein production and stability.
Lucy Sha will present key challenges that pharmaceutical companies are facing from a recent Catalent Drug Delivery Landscape Survey, and how Catalent’s drug development and delivery technologies can help to provide integrated global solutions.
Dr. Kent M. Payne is currently Vice President and General Manager and holds P&L responsibility for Catalent’s Biologics business. Beginning in 2001, he was instrumental in developing the Pharmaceutical Development outsourcing business within Cardinal Health, a Fortune 19 company. Previously he worked for the Novartis Institute for Biomedical Research, and prior to that held positions at G.D. Searle where he was also an Associate Fellow. He is a co-founder and partner of Asklepios Capital LLC, an angel investment company. He also serves as Non-Executive Board Chairman for PDS Biotechnology Corporation. As a business leader, Dr. Payne has been successful leading start-up, growth, and turn-around situations and is an advocate of Operational Excellence and Lean/Six Sigma principles.
Lucy Sha has more than 15 years global marketing experiences in the life sciences, healthcare and medical device industry. She has worked for Amersham Pharmacia Biosciences, GE Healthcare and Convatec before joining Catalent, and led marketing teams in global strategy development, new product launch, brand management and emerging market penetration. She holds a Master degree in Biochemistry and MBA in Marketing. When she was a research scientist, she worked in cancer research, large molecule discovery research and product development with patent inventionship.
To arrange a follow-up interview with Dr. Kent Payne or Lucy Sha, please contact Patricia McGee at firstname.lastname@example.org .
For more information or to register for the conference, visit: www.cphi-china.com
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.